The Open Invention Network – led by IBM, Google and 5 others – seeks a patent “no-fly zone” for open-source software. The consortium, known as the Open Invention Network, is dedicated to protecting a mode of collaborative invention. Specifically, it tries to safeguard the Linux open-source software ecosystem—software that’s written collaboratively and distributed for free—from...

A $600 million patent licensing dispute over the use of Botox to treat migraine headaches has been resolved in Allergan PLC’s favor with a U.S. judge scolding Miotox LLC for making “tedious and convoluted” arguments to prove its case.

An Asian-American rock band called The Slants asked a federal appeals court last week to trademark its name even though the government says it disparages Asians.

Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products announced that the Company has filed a patent for systems and methods for predicting treatment outcomes from chemotherapy.

One of the world’s leading aeroplane manufacturers has come up with a radical new seat design -with split-level seating inside the cabin. The arrangement proposed by Airbus designers would be used in a premium cabin such as business class with rows in the middle section alternating between floor level and an elevated level that is...

Almac Discovery, a research driven oncology company that is dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer, has announced that it has been granted patent protection (Patent Number 2040728) for its novel therapeutic drug, ALM201, in Europe, one of the largest Biopharmaceutical markets in the world. This...

Sandoz, a Novartis company and the global leader in biosimilars, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.

Indian Pharmaceutical Alliance (IPA) withdrew its opposition to the patent application for Gilead Pharmasset’s Hepatitis C drug sofosbuvir, marketed as Sovaldi, after the latter entered into a voluntary licensing agreement with 11 companies to sell the generic version at a lower price.

The Global Innovation Index (GII) 2015, released yesterday, saw India ranked a disappointing 81 out of the 141 countries surveyed. Topping the list for the 5th year running is Switzerland, followed by UK and Sweden.

Drug makers BioMarin Pharmaceutical Inc. and Dr. Reddy’s Laboratories Ltd. have agreed to settle a patent dispute over BioMarin’s Kuvan’s tablets.